检索结果-南通市图书馆

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C

World Journal of Gastroenterology 2013年第7期19卷 1098-1103页

作者： Irit Rosen Michal Kori Orly Eshach Adiv baruch yerushalmi Nataly Zion Ron Shaoul Pediatric Gastroenterology and Nutrition Unit Meyer Children's HospitalRambam Medical CenterBruce Rappaport Faculty of MedicineTechnionHaifa 31096Israel Pediatric Gastroenterology and Nutrition Unit Kaplan Medical CenterRehovot 76100Israel Pediatric Gastroenterology and Nutrition Unit Soroka Medical CenterBen Gurion University Faculty of MedicineBe'er Sheva 84101Israel

AIM:To study current treatment options for pediatric hepatitis C infection and their associated success ***:We retrospectively reviewed charts of thirty children who had been treated with combination therapy of pegylated interferon alfa plus ribavirin for chronic hepatitis C *** had been treated with ribavirin(15 mg/kg per day) and either pegylated interferon alfa 2a(180 mg/m 2 once weekly) or pegylated interferon alfa 2b(1.5 mg/kg once weekly).Patients' follow-up included subjective assessment of complaints,physical examination including weight and height,as well as laboratory evaluations for viral load [before treatment,at 12 wk,and 6 mo following treatment completion,as determined by sustained viral response(SVR)],complete blood count,liver enzymes,alkaline phosphatase,bilirubin,renal function tests,and thyroid function *** patients not achieving a two log decrease in viral load at treatment week 12,treatment was discontinued and the patient was considered a treatment ***:Thirty children aged 3-18 years were included in the *** patients(11 males,9 females) received pegylated interferon alfa 2b and ten patients(6 males,4 females) received pegylated interferon alfa ***-three patients were infected with genotype 1,six patients were infected with genotype 3,and one patient was infected with genotype *** patients(67%) achieved *** success rates were 90% with pegylated interferon alfa 2a vs 55% with pegylated interferon alfa *** a trend was noted for improved outcomes in the group receiving pegylated interferon alfa 2a,there were no statistically significant outcome differences between the two treatment groups(P = 0.1).Treatment success was 56.5% for patients infected with genotype 1 virus,compared to 100% for patients infected with other genotypes(P = 0.064).There was no difference in treatment response between males and females.A cut-off age of twelve years was used to dichotomize

关键词： Hepatitis C virus Interferon alfa Ribavirin Children Sustained viral response

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：